Apixaban: Clinical Guide
Indications
Apixaban is FDA-approved for three primary indications: 1
- Stroke prevention in nonvalvular atrial fibrillation - reduces stroke and systemic embolism risk
- VTE prophylaxis - following hip or knee replacement surgery
- VTE treatment and secondary prevention - for acute DVT/PE treatment and prevention of recurrence
Critical contraindication: Apixaban is NOT recommended for patients with prosthetic heart valves or moderate-to-severe mitral stenosis 2, and should be avoided in triple-positive antiphospholipid syndrome 1.
Dosing Recommendations
Atrial Fibrillation (Stroke Prevention)
Standard dose: 5 mg twice daily 3, 2, 1
Reduced dose: 2.5 mg twice daily ONLY if patient meets ≥2 of the following criteria: 3, 2, 1
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL (≥133 μmol/L)
Critical pitfall: Approximately 61% of patients receiving reduced-dose apixaban in clinical practice do NOT meet dose-reduction criteria 4, 5. This inappropriate underdosing is associated with significantly higher mortality (adjusted HR 1.77) without reducing bleeding risk 4. You must verify that patients meet at least 2 of the 3 criteria before prescribing 2.5 mg twice daily.
Renal Dosing in Atrial Fibrillation
Apixaban can be used across all levels of renal function (including CrCl <15 mL/min and dialysis) at either 5 mg or 2.5 mg twice daily based on the dose-reduction criteria above 3. Unlike other DOACs, apixaban does not require dose adjustment based solely on renal function for AF indication, as only 27% undergoes renal elimination 6.
VTE Prophylaxis (Post-Orthopedic Surgery)
2.5 mg twice daily - no dose adjustment needed 1
Acute VTE Treatment
10 mg twice daily for 7 days, then 5 mg twice daily 1
Important: Do NOT reduce the dose for renal dysfunction during acute VTE treatment 7. The standard treatment dose should be maintained.
VTE Secondary Prevention (After Initial Therapy)
2.5 mg twice daily 1
Recent evidence supports this reduced dose after completing 6 months of full-dose anticoagulation in cancer-associated VTE, showing 21% reduction in bleeding without loss of efficacy 8.
Contraindications
Absolute contraindications: 1
- Active pathological bleeding
- Severe hypersensitivity/anaphylactic reactions to apixaban
- Severe hepatic impairment 1
Clinical contraindications (not recommended): 2, 1
- Mechanical heart valves
- Moderate-to-severe mitral stenosis
- Triple-positive antiphospholipid syndrome
Drug Interactions Requiring Dose Adjustment
Combined P-gp AND Strong CYP3A4 Inhibitors
When using with ketoconazole, itraconazole, ritonavir, or clarithromycin: 1
- If on 5 mg or 10 mg twice daily → reduce to 2.5 mg twice daily
- If already on 2.5 mg twice daily → avoid combination or consider alternative anticoagulant
Combined P-gp AND Strong CYP3A4 Inducers
Avoid concomitant use with rifampin, carbamazepine, phenytoin, or St. John's wort - these reduce apixaban levels by >50% and compromise efficacy 1.
Monitoring Considerations
No routine laboratory monitoring is required 2, 6. However, specific situations warrant apixaban-calibrated anti-Xa level measurement:
When to Check Apixaban Anti-Xa Levels:
- Perioperative planning - especially in elderly patients with renal dysfunction who may have prolonged half-life (>10 days documented) 7
- Suspected medication non-adherence
- Extremes of body weight (<50 kg or >120 kg)
- Advanced age with multiple comorbidities
- Severe renal impairment (CrCl <30 mL/min)
- Bleeding or thrombotic events on therapy
Expected therapeutic range for anti-Xa levels: Peak 3-4 hours post-dose; half-life approximately 12 hours 6. However, in elderly patients with CKD, half-life can be significantly prolonged 7.
Perioperative Management
Timing of Discontinuation Before Surgery 3:
Low bleeding risk procedures:
- Hold for 1 full day (if CrCl >25 mL/min)
- Example: If taking 8 PM dose, skip that dose and the next morning dose for 8 AM surgery (36 hours since last dose)
High bleeding risk procedures:
- Hold for 2 full days (if CrCl >25 mL/min)
For CrCl <25 mL/min: Consider holding an additional 1-3 days, especially for high-risk procedures 3.
Key Clinical Pearls
- Bioavailability is ~50% and food does not significantly affect absorption 6
- Peak concentration occurs 3-4 hours post-dose 6
- Multiple elimination pathways (metabolism, biliary, direct intestinal, renal 27%) make it safer in renal impairment than other DOACs 6
- Intracranial hemorrhage risk is 50% lower than warfarin across all DOACs 2
- No reversal agent is FDA-approved specifically for apixaban, though andexanet alfa has shown efficacy in animal models 9
Boxed Warnings
Two critical FDA boxed warnings: 1
- Premature discontinuation increases thrombotic risk - always provide bridging anticoagulation if stopping apixaban for reasons other than bleeding or completion of therapy
- Spinal/epidural hematoma risk with neuraxial anesthesia or spinal puncture - can result in permanent paralysis; carefully time procedures relative to dosing